Taurine Ameliorates Thyroid Hypofunction and Renal Injury in L-NAME-Induced Hypertensive Rats

Abstract

There is a growing global interest in hypertension due to its associated complications including renal dysfunction in patients. The thyroid system reportedly regulates renal function in both animal and human. The present study investigated the therapeutic efficacy of taurine on renal and thyroid dysfunctions in hypertensive rats. Hypertension was induced by oral administration of nitric oxide synthase inhibitor, N-nitro L-arginine-methyl-ester (L-NAME), at 40 mg/kg body weight to the male Wistar rats for 14 consecutive days. The hypertensive rats were subsequently treated with either taurine (100 and 200 mg/kg) or reference drug atenolol (10 mg/kg) for another 14 consecutive days. Hypertensive rats showed renal damage evidenced by elevated plasma creatinine and urea levels when compared with normotensive control rats. Furthermore, L-NAME-induced hypertensive rats showed decreased circulatory concentrations of thyroid stimulating hormone, thyroxine, triiodothyronine and the ratio of triiodothyronine to thyroxine. The marked decrease in the renal antioxidant enzyme activities and nitric oxide level was accompanied by significant increase in myeloperoxidase activity and biomarkers of oxidative stress in hypertensive rats. Histological examination of kidneys from hypertensive rats revealed congestion of blood vessels, hemorrhagic lesion and disorganized glomerular structure. However, treatment with taurine or atenolol significantly reversed the suppression of thyroid function, ameliorated renal oxidative stress and histopathological lesions in L-NAME-induced hypertensive rats. Taurine may be a useful chemotherapeutic supplement in enhancing renal and thyroid functions in hypertensive patients.

Key words

Hypertension - taurine - renal injury - thyroid function - rats

• References

• 1 Sternlicht H, Bakris GL. The kidney in hypertension. Med Clin North Am 2017; 101: 207-217
• 2 United States Renal Data System . Annual data report. Incidence and prevalence of ESRD. Am J Kidney Dis 1997; 30: S40-S53
• 3 Axon RN, Turner M, Buckley R. An Update on inpatient hypertension management. Curr Cardiol Rep 2015; 17: 94
• 4 Roszkowska-Blaim M, Skrzypczyk P. Hypertension in children with end-stage renal disease. Adv Med Sci 2015; 60: 342-348
• 5 Hsu CY, McCulloch CE, Darbinian J. et al. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med. 2005; 165: 923-928
• 6 National Institute of Diabetes and Digestive and Kidney Diseases . United States renal data system 2012 annual data report: Volume 2: Atlas of end-stage renal disease in the United States. Washington, D.C.: U.S. Government Printing Office; 2012. Report
• 7 Kabedi NN, Mwanza JC, Lepira FB. et al. Hypertensive retinopathy and its association with cardiovascular, renal and cerebrovascular morbidity in Congolese patients. Cardiovasc J Afr 2014; 25: 228-232
• 8 Nansseu JR, Noubiap JJ, Mengnjo MK. et al. The highly neglected burden of resistant hypertension in Africa: A systematic review and meta-analysis. BMJ Open 2016; 6: e011452
• 9 Marín R, Gorostidi M, Fernández-Vega F. et al. Systemic and glomerular hypertension and progression of chronic renal disease: The dilemma of nephrosclerosis. Kidney Int 2005; 99: S52-S56
• 10 Nosalski R, McGinnigle E, Siedlinski M. et al. Novel immune mechanisms in hypertension and cardiovascular risk. Curr Cardiovasc Risk Rep 2017; 11: 12
• 11 Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: What is the clinical significance?. Hypertension 2004; 44: 248-252
• 12 Redon J, Oliva MR, Tormos C. et al. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003; 41: 1096-1101
• 13 Dikalov SI, Dikalova AE. Contribution of mitochondrial oxidative stress to hypertension. Curr Opin Nephrol Hypertens. 2016; 25: 73-80
• 14 Kaptein EM. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. Endocr Rev 1996; 17: 45-63
• 15 Iglesias P, Díez JJ. Thyroid dysfunction and kidney disease. Euro J Endocrinol 2009; 160: 503-515
• 16 Rhee CM. The interaction between thyroid and kidney disease: An overview of the evidence. Curr Opin Endocrinol Diabetes Obes 2016; 23: 407-415
• 17 Den Hollander JG, Wulkan RW, Mantel MJ. et al. Correlation between severity of thyroid dysfunction and renal function. Clin Endocrinol 2005; 62: 423-427
• 18 Gopinath B, Harris DC, Wall JR. et al. Relationship between thyroid dysfunction and chronic kidney disease in community-dwelling older adults. Maturitas 2013; 75: 159-164
• 19 Vargas F, Moreno JM, Rodríguez-Gómez I. et al Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol. 2006; 154: 197-212
• 20 Morgado E, Neves PL. Hypertension and chronic kidney disease: Cause and consequence – Therapeutic considerations, antihypertensive drugs, Prof. Hossein Babaei (Ed.), ISBN: 978-953-51-0462-9, InTech; 2012;
• 21 Huxtable RJ. The physiological actions of taurine. Physiol Rev 1992; 72: 101-163
• 22 Das J, Roy A, Sil PC. Mechanism of the protective action of taurine in toxin and drug induced organ pathophysiology and diabetic complications: A review. Food Funct 2012; 3: 1251-1264
• 23 Adedara IA, Abolaji AO, Idris UF. et al. Neuroprotective influence of taurine on fluoride-induced biochemical and behavioral deficits in rats. Chem Biol Interact 2017; 261: 1-10
• 24 De Luca A, Pierno S, Camerino DC. Taurine: The appeal of a safe amino acid for skeletal muscle disorders. J Transl Med 2015; 13: 243-251
• 25 Xu YJ, Arneja AS, Tappia PS. et al. The potential health benefits of taurine in cardiovascular disease. Exp Clin Cardiol 2008; 13: 57-65
• 26 Hu J, Xu X, Yang J. et al. Antihypertensive effect of taurine in rat. Adv Exp Med Biol 2009; 643: 75-84
• 27 Shao A, Hathcock JN. Risk assessment for the amino acids taurine, L-glutamine and L-arginine. Regul Toxicol Pharmacol 2008; 50: 376-399
• 28 Yamori Y, Taguchi T, Hamada A. et al. Taurine in health and diseases: Consistent evidence from experimental and epidemiological studies. J Biomed Sci. 2010; 17: S6
• 29 Roysommuti S, Suwanich A, Jirakulsomchok D. et al. Perinatal taurine depletion increases susceptibility to adult sugar-induced hypertension in rats. Adv Exp Med Biol 2009; 643: 123-133
• 30 Rahman MM, Park HM, Kim SJ. et al. Taurine prevents hypertension and increases exercise capacity in rats with fructose-induced hypertension. Am J Hypertens 2011; 24: 574-581
• 31 Cardoso AM, Abdalla FH, Bagatini MD. et al. Swimming training prevents alterations in acetylcholinesterase and butyryl cholinesterase activities in hypertensive rats. Am J Hypertens 27 2014; 522-529
• 32 Akinyemi AJ, Adedara IA, Thome GR. et al. Dietary supplementation of ginger and turmeric improves reproductive function in hypertensive male rats. Toxicol Rep 2015; 2: 1357-1366
• 33 National Research Council . Guide for the Care and Use of Laboratory Animals. Washington: National Academies Press; 2011
• 34 Talas ZS. Propolis reduces oxidative stress in L-NAME-induced hypertension rats. Cell Biochem Funct 2014; 32: 150-154
• 35 Adedara IA, Alake SE, Adeyemo MO. et al. Taurine enhances spermatogenic function and antioxidant defense mechanisms in testes and epididymis of L-NAME-induced hypertensive rats. Biomed Pharmacother 2018; 97: 181-189
• 36 Bradford MM. A rapid and sensitive for the quantitation of microgram quantitites of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
• 37 Misra HP, Fridovich I. The role of superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972; 247: 3170-3175
• 38 Clairborne A. Catalase activity. In: Greewald AR. (ed.) Handbook of Methods for oxygen radical research. Boca Raton, FL: CRC Press; 1995. pp 237-242
• 39 Jollow DJ, Mitchell JR, Zampaglione N. et al. Bromobenzene induced liver necrosis: Protective role of glutathione and evidence for 3, 4 bromobenzene oxide as the hepatotoxic metabolite. Pharmacology 1974; 11: 151-169
• 40 Rotruck JT, Pope AL, Ganther HE. et al. Selenium: Biochemical role as a component of glutathione peroxidase. Science 1973; 179: 588-590
• 41 Wolff SP. Ferrous ion oxidation in the presence of ferric ion indicator xylenol orange for measurement of hydroperoxides. Methods Enzymol 1994; 233: 182-189
• 42 Farombi EO, Tahnteng JG, Agboola AO. et al. Chemoprevention of 2-acetylaminofluorene-induced hepatotoxicity and lipid peroxidation in rats by kolaviron-a Garcinia kola seed extract. Food Chem Toxicol 2000; 38: 353-541
• 43 Granell S, Gironella M, Bulbena O. et al. Heparin mobilizes xanthine oxidase and induces lung inflammation in acute pancreatitis. Crit Care Med 2003; 31: 525-530
• 44 Green LC, Wagner DA, Glogowski J. et al. Analysis of nitrate, nitrite and [15 N] nitrate in biological fluids. Anal Biochem 1982; 126: 131-138
• 45 Bancroft JD, Gamble M. Theory and practice of histology techniques. 6th edition Churchill Livingstone Elsevier; 2008. pp 83 - 134
• 46 Whitworth JA. Progression of Renal Failure – The Role of Hypertension. Ann Acad Med Singapore 2005; 34: 8-15
• 47 Silambarasan T, Manivannan J, Raja B. et al. Prevention of cardiac dysfunction, kidney fibrosis and lipid metabolic alterations in L-NAME hypertensive rats by sinapic acid – Role of HMG-CoA reductase. Eur J Pharmacol. 2016; 777: 113-123
• 48 Rajeshwari T, Raja B, Manivannan J. et al. Valproic acid prevents the deregulation of lipid metabolism and renal renin-angiotensin system in L-NAME induced nitric oxide deficient hypertensive rats. Environ Toxicol Pharmacol. 2014; 37: 936-945
• 49 Adedara IA, Teberen R, Ebokaiwe AP. et al. Induction of oxidative stress in liver and kidney of rats exposed to Nigerian bonny light crude oil. Environ Toxicol 2012; 27: 372-379
• 50 Fonseca TL, Correa-Medina M, Campos MP. et al. Coordination of hypothalamic and pituitary T₃ production regulates TSH expression. J Clin Invest 2013; 123: 1492-1500
• 51 Gereben B, Zavacki AM, Ribich S. et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev 2008; 29: 898-938
• 52 Fellet AL, Arza P, Arreche N. et al. Nitric oxide and thyroid gland: Modulation of cardiovascular function in autonomic-blocked anaesthetized rats. Exp Physiol 2004; 89: 303-312
• 53 Montenegro J, Gonzalez O, Saracho R. et al. Changes in renal function in primary hypothyroidism. Am J Kidney Dis 1996; 27: 195-198
• 54 Gardiner SM, Compton AM, Bennett T. et al. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 1990; 15: 486-492
• 55 Kato Y. Neutrophil myeloperoxidase and its substrates: Formation of specific markers and reactive compounds during inflammation. J Clin Biochem Nutr. 2016; 58: 99-104
• 56 Rosen H, Crowley JR, Heinecke JW. Human neutrophils use the myeloperoxidase hydrogen peroxide-chloride system to chlorinate but not nitrate bacterial proteins during phagocytosis. J Biol Chem 2002; 277: 30463-30468
• 57 Berkels R, Egink G, Marsen TA. et al. Nifedipine Increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension 2001; 37: 240-245
• 58 Mihalj M, Tadzic R, Vcev A. et al. Blood pressure reduction is associated with the changes in oxidative stress and endothelial activation in hypertension, regardless of antihypertensive therapy. Kidney Blood Press Res 2016; 41: 721-735
• 59 Reis GS, Augusto VS, Silveira AP. et al. Oxidative-stress biomarkers in patients with pulmonary hypertension. Pulm Circ 2013; 3: 856-861
• 60 Dekleva M, Lazic JS, Arandjelovic A. et al. Beneficial and harmful effects of exercise in hypertensive patients: the role of oxidative stress. Hypertens Res 2017; 40: 15-20
• 61 Rajeshwari T, Raja B, Manivannan J. et al. Valproic acid prevents the deregulation of lipid metabolism and renal renin-angiotensin system in L-NAME induced nitric oxide deficient hypertensive rats. Environ Toxicol Pharmacol 2014; 37: 936-945
• 62 Kashyap S, Boyilla R, Zaia PJ. et al. Development of renal atrophy in murine 2 kidney 1 clip hypertension is strain independent. Res Vet Sci 2016; 107: 171-177